Search the Newsreel

Viatris (Nasdaq: VTRS) grows Q2 revenue, raises 2026 outlook

Viatris faces earnings test as pipeline progress meets pricing pressure

Viatris Inc. is preparing to announce its second-quarter earnings, with analysts anticipating $0.61 EPS on $3.67 billion in revenue. Investors are keenly watching whether the company's recent pipeline successes, such as FDA acceptance for fast-acting meloxicam and positive Phase 3 results for VR-205, can …

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Viatris (VTRS) is expected to announce its Q2 earnings, with analysts predicting $0.62 per share and revenues of $3.68 billion, a 2.6% increase year-over-year. The consensus EPS estimate has seen a 1% downward revision in the past 30 days. Key metric forecasts include Net …

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

Viatris (VTRS) is set to announce its second-quarter 2026 earnings on August 6th, with analysts expecting revenues of $3.68 billion and earnings per share of 62 cents. The company's performance will be influenced by factors such as geographical segment sales (Developed Markets, Emerging Markets, …

Is Wall Street Bullish or Bearish on Viatris Stock?

Image by Jakub Zerdzicki via Unsplash With a market cap of $20.5 billion, Viatris Inc. (VTRS) is a global healthcare company committed to empowering people worldwide to live healthier lives at every stage. With a diverse portfolio spanning generics, established brands, and innovative medicines, …

Viatris declares $0.12 quarterly dividend per share By Investing.com

Viatris Inc. announced that its Board of Directors has declared a quarterly dividend of $0.12 per share. This dividend will be paid to shareholders of record as of August 21, 2026, with the payment date set for September 16, 2026. The announcement was made …

Viatris Announces Quarterly Dividend

Viatris Inc. (Nasdaq: VTRS) announced that its Board of Directors declared a quarterly dividend of $0.12 per share. The dividend is payable on September 16, 2026, to shareholders of record as of August 21, 2026. The company also included a section on forward-looking statements …

Viatris (VTRS) Q2 Earnings Report Preview: What To Look For

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris Inc. (Nasdaq: VTRS) announced it will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET. Investors and the public can listen to the live webcast on the company's investor …

Viatris (VTRS) Stock May Be Cheap Following Its 107% 1 Year Run

PFE5282055 Bond Profile — Key Metrics

This article provides key metrics for the Viatris Inc. (PFE5282055) corporate bond, including its issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. It also offers a brief overview of Viatris Inc.'s business operations and segments. The bond has an issue …

Viatris Inc. stock falls Friday, underperforms market

Viatris Inc. (VTRS) stock fell 1.13% on Friday, closing at $17.56, despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for Viatris …

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?

Viatris (VTRS) is expected to report flat earnings for Q2 2026 compared to the previous year, but with a 2.8% increase in revenues to $3.68 billion. The Zacks Earnings ESP indicates a potential negative surprise for Viatris, as the Most Accurate Estimate is lower …

What Viatris (VTRS)'s FDA Approval of Weekly Gwyn Lo Contraceptive Patch Means For Shareholders

Viatris (VTRS) recently received FDA approval for Gwyn Lo, a new weekly low-estrogen contraceptive patch, which is expected to diversify its product mix towards higher-margin, branded offerings. This approval supports the company's strategy to shift from a generics-heavy portfolio to more complex and branded …

Viatris Inc (VTRS) Risk Assessment: Volatility, Financial Risk & Investment Risk

Viatris Inc (VTRS) has a current risk assessment score of 8.80, placing it 21st out of 155 in the Pharmaceuticals industry. The company's beta of 0.89 indicates it tends to underperform during market uptrends but experiences smaller declines during downturns. The report details various …

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. announced that the U.S. FDA has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen patch is indicated for women of childbearing potential with a BMI below 30 kg/m² and demonstrated efficacy and a well-characterized safety profile in …

Viatris Number of Employees 2026 | Employee Count & Headcount Data

Viatris, Inc. (NASDAQ: VTRS) reported approximately 29,935 global employees as of March 2026, marking a 3.8% decline from 2023. The company is actively hiring with 474 open job postings in 2026, a 10.7% increase from 2025. Viatris's workforce is primarily located in India (43.1%), …

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with …

Viatris Inc. stock rises Tuesday, outperforms market

Viatris Inc. (VTRS) stock rose 1.28% on Tuesday, closing at $17.86. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw gains. The increase marks the second consecutive day of gains for Viatris stock.

Viatris Inc (VTRS) Income Statement

This article provides the quarterly and annual income statements for Viatris Inc (VTRS), offering detailed financial data such as total revenue, cost of revenue, operating expenses, operating profit, net income, and earnings per share (EPS). It includes year-over-year percentage changes and absolute figures across …

Viatris Inc (VTRS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Viatris Inc.'s (VTRS) shareholder structure, listing major shareholders and their proportionate holdings, along with institutional ownership trends over recent quarters. It also categorizes shareholders by type and lists ETFs with significant VTRS holdings.

Viatris stock hits 52-week high at $17.68

Viatris Inc. (VTRS) stock reached a 52-week high of $17.68, reflecting strong market performance with a 90.82% surge over the past year and a 2.78% dividend yield. The pharmaceutical company is considered undervalued by InvestingPro, with recent positive news including exceeding Q1 2026 financial …

Viatris, Inc. Revenue Breakdown – BX:VTRS

Viatris, Inc. (VTRS) generated 11.34 billion CHF last year, with its "Brands" segment contributing the most at 7.28 billion CHF. The company's largest revenue contribution came from Developed Markets, accounting for 4.37 billion CHF. This data provides a snapshot of Viatris's key revenue drivers …

PFE5003244 Bond Risk Profile

This article provides a risk profile for the PFE5003244 bond issued by Viatris Inc., maturing on June 22, 2030, with a 2.7% coupon rate. It focuses on key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors …

PFE5282056 Bond Profile — Key Metrics

This article provides a detailed profile of the PFE5282056 bond issued by Viatris, Inc. Key metrics include its 2.7% coupon rate, maturity date of June 22, 2030, and an outstanding amount of $1.45 billion. The piece also gives an overview of Viatris Inc., describing …

Viatris Inc. stock rises Thursday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.59% to $17.28 on Thursday, outperforming the broader market which saw the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) decline. The company's stock closed 2.23% below its 52-week high of $17.68. This rise occurred during …

Viatris, Inc. (VIA) Q2 2023 Earnings Report - Results, Call & Slides

Viatris, Inc. (VIA) reported its Q2 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of €0.66 against a consensus of €0.62, and actual revenue of €3.43 billion against an expected €3.38 billion. The report includes details from the …

Viatris’ Quarterly Earnings Preview: What You Need to Know

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris …

PFE5003244 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the PFE5003244 bond issued by Viatris Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 2.70%, with the next payment expected on December 22, 2026. The article highlights how to …

FDA slaps Sanofi, Viatris with Untitled Letters over promotional emails, TV ad

The FDA has issued Untitled Letters to Sanofi and Viatris regarding their promotional materials. Viatris received a letter for a TV ad about Tobi Podhaler, which implied broader usage than approved, while Sanofi was cited for promotional emails for Beyfortus that misrepresented its RSV …

Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership?

Viatris (VTRS) has partnered with the American Academy of Orthopaedic Surgeons (AAOS) to launch an online Pain Management Resource Center, reflecting its strategic focus on musculoskeletal pain care. While this initiative aligns with Viatris's push into higher-value pain treatments, the article highlights that the …

PFE5003242 Bond Profile — Key Metrics

This article provides a bond profile for PFE5003242, a Viatris Inc. bond with a 2.3% coupon maturing on June 22, 2027. It details key metrics such as issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also includes …

Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon

Khaitan & Co advised Viatris Inc. on the secondary sale of its shares in Biocon Limited. The transaction involved a total consideration of INR 3680 crore (USD 385.9 million) through stock exchange sales. The legal team from Khaitan & Co was led by Rabindra …

Viatris stock hits 52-week high at $17.54 By Investing.com

Viatris Inc. stock reached a 52-week high of $17.53, reflecting a 94% increase over the past year and 41% year-to-date returns. InvestingPro analysis suggests the stock is undervalued, with further upside potential. The company recently reported strong Q1 2026 financial results exceeding analyst expectations …

Viatris Inc. stock rises Wednesday, outperforms market

Viatris Inc. (VTRS) stock increased by 2.27% on Wednesday, closing at $16.68. The rise came during an overall positive trading session, with the S&P 500 Index gaining 0.38% and the Dow Jones Industrial Average gaining 0.29%. The stock is currently 4.85% below its 52-week …

Viatris range-top rebound lacks a volume kicker despite a 44-week Trend Signal

Viatris rose 6.2% for the week and remains high in its 52-week range, but average participation and an undecided expectancy read keep the setup balanced.